CD7 and acute lymphoblastic leukemia: CD7 is uniformly and strongly positive in T-lymphoblastic leukemia/lymphoma (T-ALL) and remains highly expressed during chemotherapy and at relapse [31,32], and therefore, CD7 is a promising therapeutic target.